Identification of Antileukemic Compound From Ginger by Integrating UHPLC–MS, Network Pharmacology, Molecular Docking, Molecular Dynamics Simulation, and In Vitro and In Vivo Experimental Validation
Mengjun Huang, Jing Liu, Kaixuan Zeng, Lianling Xu, Yangchun Liu, Linyun Xie, Mengni Shi, Yan Zeng, Wenjun Liu, Ling Guo · 2026
Read Identification of Antileukemic Compound From Ginger by Integrating UHPLC–MS, Network Pharmacology, Molecular Docking, Molecular Dynamics Simulation, and In Vitro and In Vivo Experimental Validation by Mengjun Huang, Jing Liu, Kaixuan Zeng, Lianling Xu, Yangchun Liu, Linyun Xie, Mengni Shi, Yan Zeng, Wenjun Liu, Ling Guo (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13583061.txt.
Description
Huang and a large team present a study from twenty twenty-six on a ginger compound that fights acute myeloid leukemia. The cancer resists drugs and relapses often, so safer plant options draw interest. Extracts from four ginger types kill leukemia cells in tests. Profiling singles out one compound, arctigenin, for deeper study. Its presence in the extracts is confirmed with a standard sample. The compound kills leukemia cells strongly and selectively. Computer docking points to two proteins as likely targets.
Cell tests show the compound triggers cell death and shifts those proteins. In mice, it shrinks tumors about as well as a standard drug. No liver, spleen, or metabolic harm appears in the animals. The authors back ginger as a new source for leukemia therapy ideas.
Catalog record
| CREATOR | Mengjun Huang, Jing Liu, Kaixuan Zeng, Lianling Xu, Yangchun Liu, Linyun Xie, Mengni Shi, Yan Zeng, Wenjun Liu, Ling Guo |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |